Breast Cancer Clinical Trial
Official title:
A Randomised, Double-Blind Trial to Assess the Effects on Bone Mineral Density and Bone Biomarkers of Anastrozole When Used to Prevent Breast Cancer in Postmenopausal Women
RATIONALE: Bisphosphonates, such as risedronate, may help improve bone health and prevent
osteoporosis in postmenopausal women. It is not yet known whether risedronate is effective
in improving bone mineral density and bone health in women with ductal carcinoma in situ.
PURPOSE: This randomized phase III trial is studying risedronate to see how well it works
compared to a placebo in improving bone mineral density and bone health in postmenopausal
women with ductal carcinoma in situ enrolled in clinical trial CRUK-IBIS-II-DCIS (CRUK:
Cancer Research UK) (DCIS: Ductal carcinoma in situ).
OBJECTIVES:
Primary
- Compare the changes in bone of the spine and femur in postmenopausal women with ductal
carcinoma in situ treated with anastrozole vs placebo on protocol CRUK-IBIS-II-DCIS.
- Determine the effect of bisphosphonate treatment on bone mineral density and bone
metabolism in patients who are receiving anastrozole on protocol CRUK-IBIS-II-DCIS and
are osteoporotic or moderately to severely osteopenic at baseline.
Secondary
- Correlate changes in levels of biochemical markers of bone metabolism with longer-term
changes in bone mineral density, as measured by dual-energy x-ray absorptiometry (DXA).
OUTLINE: This is a multicenter, partially randomized, double-blind study. Patients are
stratified according to bone mineral density (T-score) measurements (≥ -1.5 vs -2.5 to <
-1.5 vs -4.0 to < -2.5 or ≤ 2 low-trauma vertebral fractures). Patients in stratum I are
further stratified according to calcium and cholecalciferol (vitamin D) supplementation (yes
vs no) and use of risedronate on this study (yes vs no). Patients in stratum II are further
stratified according to randomized treatment on protocol CRUK-IBIS-II-DCIS (yes vs no).
- Stratum I (T-score ≥ -1.5): Patients undergo dual-energy x-ray absorptiometry (DXA)
scanning at baseline and then at 1, 3, 5, and 7 years. Patients who develop
osteoporosis (T-score < -2.5) are removed from the study and receive open-label
bisphosphonates.
- Stratum II (T-score -2.5 to < -1.5 [moderate to severe osteopenia]): Patients undergo
DXA scanning as in stratum I. Patients are also randomized (double-blind) to 1 of 2
treatment arms.
- Arm I: Patients receive oral risedronate once a week for 5 years.
- Arm II: Patients receive oral placebo once a week for 5 years. Patients in either
arm who develop osteoporosis AND a drop in T-score of more than 1 unit are removed
from the study and receive open-label bisphosphonates.
- Stratum III (T-score -4.0 to < -2.5 OR ≤ 2 low trauma vertebral fractures
[osteoporosis]): Patients undergo DXA scanning as in stratum I. Patients also receive
oral risedronate (or their current bisphosphonate) once a week for 5 years.
Blood samples for correlative studies (e.g., bone biomarkers, serum estradiol) are collected
at baseline and at 6 and 12 months.
After completion of study treatment, patients are followed periodically.
PROJECTED ACCRUAL: A total of 1,000 patients will be accrued for this study.
;
Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |